



# WE GO BEYOND TO ENABLE TRANSFORMATION

Company Factbook 2026



# Evonik at a glance

**€14.1 bn**

Sales

**€1.9 bn** (13.3%)

Adj. EBITDA (margin)

**€695 m** (37%)

Free Cash Flow (conversion)

**6.1%**

ROCE

**€1.00**

Dividend per share<sup>1</sup>

**LEADING  
BEYOND  
CHEMISTRY**

## Custom Solutions

Innovation-driven  
businesses with  
**tailored** and  
**science-based**  
solutions



## Advanced Technologies

Efficiency-driven  
businesses with a high  
level of **technological**  
**expertise** and  
**operational**  
**excellence**



FY 2025 | 1. For fiscal year 2025, to be paid in 2026

# Why invest in Evonik?

## EVONIK IS INDUSTRY'S SUPERFORCE

### Tailored solutions and industrial excellence



#### Leading Portfolio

*We are best positioned for the future, after a profound transformation*



#### Sustainable Innovation

*We are banking on sustainable innovation as major growth-driver*



#### Regional Balance

*We are striving for a regionally balanced footprint*



#### Team Excellence

*We are engaged as a team*



#### Shareholder Return

*We are committed to consistent and attractive returns for our shareholders*

...with our leading portfolio structured in two distinct, complementary business models under one roof


...with Next Generation Solutions, process innovation (Next Generation Technologies) and our three Innovation Growth Areas

...targeting an equal sales distribution across all regions; our local-for-local approach is ensuring supply security and cost competitiveness

...delivering on our promises, executing on our strategy, even succeeding in a continued tough environment


...through disciplined capital allocation, focused on organic growth and an attractive dividend

# Our product portfolio: End market split and product examples



# Ownership structure: RAG-Stiftung as long-term shareholder

## Ownership structure



## RAG-Stiftung

- RAG-Stiftung (foundation) manages a portfolio of ~€18 bn assets, one of the biggest foundations in Europe
- Portfolio consists of publicly traded securities, private equity, direct holdings, real estate and bonds of various types
- RAG-Stiftung focuses on investments with high total shareholder return and strong cash/distribution profiles
- Underlying goal is to finance/cover the perpetual obligations arising from hard-coal mining in Germany
- About 75% of total portfolio invested in assets other than Evonik

### Bernd Tönjes, chairman of the RAG-Stiftung (June 11, 2024):

"The long-term goal was and is to hold 25.1% in Evonik ... We currently still have exchangeable bonds corresponding to almost 20% of Evonik shares that we hold for a possible exchange at maturity. If you have now done the math, you will find that there is not much missing from the aforementioned 25.1% and **thus the much-cited "overhang" no longer exists.**"

# Click the table of contents to navigate chapters

---

## 1 Strategy

- 1.1 Leading Portfolio
- 1.2 Sustainable Innovation
- 1.3 Regional Balance
- 1.4 Team Excellence

## 2 Segments

- 2.1 Custom Solutions
- 2.2 Advanced Technologies

## 3 Financials

- 3.1 Main KPI's
- 3.2 Financial Strategy

# Click the table of contents to navigate chapters

---

## 1 Strategy

### 1.1 Leading Portfolio


### 1.2 Sustainable Innovation

### 1.3 Regional Balance

### 1.4 Team Excellence









# Leading Portfolio

## New segment structure with tangible benefits



# Leading Portfolio

## Custom Solution and Advanced Technologies – Overview and KPI's

	Custom Solutions		Advanced Technologies	
Financials 2025	 Sales <b>€5.5 bn</b>	 EBITDA <b>€909 m</b>	 Sales <b>€5.9 bn</b>	 EBITDA <b>€944 m</b>
	 ROCE <b>10%</b>	 EBITDA-margin <b>17%</b>	 ROCE <b>7%</b>	 EBITDA-margin <b>16%</b>
Role	Stronger role as growth driver with superior EBITDA growth		Stronger financing role with superior cash flow generation	
Focus KPI's	<b>Innovation-centric KPI's</b> <ul style="list-style-type: none"> <li>▪ Share of new product sales</li> <li>▪ Share of “Next Generation Solutions”</li> <li>▪ Speed of idea to market</li> </ul>		<b>Customer-centric KPI's</b> <ul style="list-style-type: none"> <li>▪ Customer / Service satisfaction</li> <li>▪ Order fulfilment / reliability</li> <li>▪ Opportunity management</li> <li>▪ Share of customized products</li> </ul>	
			<b>Technological KPI's</b> <ul style="list-style-type: none"> <li>▪ Off-spec ratio</li> <li>▪ Cost to build</li> <li>▪ Net overall equipment effectiveness</li> </ul>	

FY 2025

# Leading Portfolio

## Custom Solution and Advanced Technologies – Products and end markets

	Additives	Care	Organics	Inorganics	Animal Nutrition
Sub-segments					
Main products	<ul style="list-style-type: none"> <li>▪ Coating Additives</li> <li>▪ Polyurethane Additives</li> <li>▪ Lubricant Additives</li> <li>▪ Other Industrial Additives</li> <li>▪ Catalysts</li> </ul>	<ul style="list-style-type: none"> <li>▪ Home, Lifestyle, Personal Care</li> <li>▪ Health Care</li> </ul>	<ul style="list-style-type: none"> <li>▪ Crosslinkers</li> <li>▪ High Performance Polymers (e.g. PA12)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Hydrogen Peroxide</li> <li>▪ Silica/ Silanes</li> </ul>	<ul style="list-style-type: none"> <li>▪ Amino Acids (e.g. Methionine)</li> </ul>
Selected end markets	<ul style="list-style-type: none"> <li>▪ Automotive</li> <li>▪ Construction</li> <li>▪ Food &amp; Beverage</li> <li>▪ Agriculture</li> <li>▪ Medical applications</li> </ul>	<ul style="list-style-type: none"> <li>▪ Cleaning</li> <li>▪ Personal Care</li> <li>▪ Pharmaceutical Industry</li> <li>▪ Beauty</li> </ul>	<ul style="list-style-type: none"> <li>▪ Automotive</li> <li>▪ Construction</li> <li>▪ Wind power</li> <li>▪ Electronics</li> <li>▪ Oil &amp; Gas</li> </ul>	<ul style="list-style-type: none"> <li>▪ Tires</li> <li>▪ Pulp &amp; Paper</li> <li>▪ Oral Care</li> <li>▪ Electronics</li> <li>▪ Food &amp; Beverages</li> </ul>	<ul style="list-style-type: none"> <li>▪ Animal Feed</li> <li>▪ Specialty feed additives</li> <li>▪ Sus. Omega-3 fatty acids</li> </ul>

■ Custom Solutions
 ■ Advanced Technologies

# Leading Portfolio

We continue to transform the portfolio

— **Today** ————— **2027** ————— **Long-term** —→

**New segments & differentiated business steering**

Divestment of **Performance Intermediates** (*Oxeno - C4, sales ~€1.9 bn*)

Decision and execution on future of **Marl  
and Wesseling** (*SYNEQT, sales >€1.8 bn*)

Portfolio finetuning in **Health Care and  
Coatings & Adhesive Resins** (*total sales >€350 m*)

Further portfolio finetuning

## Ongoing portfolio management

- Focus within existing segment structure
- Strengthening innovation growth areas
- Aiming for a balanced regional split
- Continuous review of competitiveness of assets

# Click the table of contents to navigate chapters

---

## 1 Strategy

1.1 Leading Portfolio

**1.2 Sustainable Innovation**

1.3 Regional Balance

1.4 Team Excellence

# Sustainable Innovation

## Main growth driver for the long-run

### Product innovation



€1.5 bn additional sales by 2032 at >20% margin

Next Generation Solutions<sup>1</sup> with superior sustainability profile

**NEXTGEN**   
Solutions

Advance  
Precision  
Biosolutions

Enable  
Circular  
Economy

Accelerate  
Energy  
Transition

### Process innovation



Drive cost leadership and reduce GHG<sup>2</sup> emissions  
Next Generation Technology projects with avg. >25% IRR

**NEXTGEN**   
Technologies

Advanced  
Process Control

Innovative  
waste heat  
up-cycling



Process  
redesign

1. Next Generation Solutions; products with superior sustainability profile according to our PSA analysis | 2. Green house gas emissions

# Evonik product portfolio is geared towards Next Generation Solutions (NGS) with a superior sustainability profile and above-average growth

Sales growth 2024-2030E (in %)

NGS sales share in 2025 (in %)



+3pp

**Next Generation Solutions**

Increased from 45 to ~48%; well on track for target of >50% by 2030


**NEXTGEN**   
Solutions

- Deliver superior sustainability benefits to our customers
- Address increasing customer demand for sustainable solutions
- Substitute less sustainable solutions in the market
- Deliver above-average growth

Next Generation Solutions (NGS) = products with superior sustainability profile according to our Portfolio Sustainability Assessment (PSA) according to the World Council for Sustainable Development (WBCSD)

# Innovation: New Innovation Growth Areas address the most pressing challenges of our time where Evonik can make a difference

## WE GO BEYOND TO ENABLE THE GREEN TRANSFORMATION



**Advance  
Precision  
Biosolutions**



**Enable  
Circular  
Economy**



**Accelerate  
Energy  
Transition**

Develop new products and solutions that will distinctively stand out on the market and have a positive influence on society and people's everyday life


- **Sustainability:** Solutions for a bio-based, energy-efficient, and circular society
- **Resilience:** Strong growth potential, above-average margins
- **Focus:** Majority of R&D resources allocated to Innovation Growth Areas
- **Acceleration:** Supported by Creavis, Evonik Venture Capital, and regional innovation ecosystems

**Sales increase 2023 to 2032: €1.5 billion**

# We enable high-performing and sustainable solutions for our customers – circled around our three innovation growth areas

## WE GO BEYOND TO ENABLE THE GREEN TRANSFORMATION

### Advance Precision Biosolutions



*Selected product examples:*

- Cosmetic Actives
- Biosurfactants
- SkinMicrobes Model
- Nucleic acid-based medicines

### Enable Circular Economy



*Selected product examples:*

- Additives for PU recycling
- Devulcanization aids for rubber recycling
- Ceramic membranes for lithium battery recycling

### Accelerate Energy Transition



*Selected product examples:*

- Gas separation Membranes
- Anion Exchange Membranes
- Solid-state batteries
- Carbon Capture (from point sources and directly from the air)

# Sustainability as backbone of Evonik's purpose and strategy

## Clear commitment to growing handprint and reducing footprint

### Sustainability is an integral part of our purpose



“We see profitable growth and assuming responsibility as **two sides of the same coin.**”

### Key growth driver...

### ...and saving resources

#### Our Handprint



“Sustainability is a **key growth driver** and the cornerstone of our product portfolio, our investments and our innovation management.”

#### Our Footprint



“We **take responsibility** by **caring about our resources.**”

### Core elements of our sustainability approach

**1** Evonik fully integrates sustainability in its **Strategic Management Process**



**2** Evonik intends to **increase the portfolio share** of products with **sustainability benefits**



**3** Evonik is committed to foresighted **resource management**




**4** Evonik with high standards for **governance** and continuous **improvement of its reporting**



# ESG Ratings

## Evonik best-in-class within chemicals sector



1: Rating on a scale of AAA to CCC | 2: Top 5% of companies assessed | 3: Rating on a scale of A+ to D- | 4: out of ~600 companies ranked in the chemical sector | 5: Rating on a scale of A+ to D-

**Discover more details  
in our ESG factbook  
on our website**

# Click the table of contents to navigate chapters

---

## 1 Strategy

1.1 Leading Portfolio


1.2 Sustainable Innovation

**1.3 Regional Balance**

1.4 Team Excellence

# Regional Balance:

Aiming for 1/3 of sales in each region to be close to our customers



1. Excluding Performance Intermediates (C4)

# Regional Balance

## Portfolio change and investments drive changing sales split



Target sales share

EMEA  
1/3

Asia-Pacific  
1/3

↓ Intended divestments in Europe (€2.4 bn external sales)

Oxeno (C4 business),  
Germany

Infrastructure  
Marl & Wesseling,  
Germany



↑ Investments in Asia

Amines,  
China

Alkoxides,  
Singapore

Metal Oxides,  
Japan



# Click the table of contents to navigate chapters

---

## 1 Strategy

1.1 Leading Portfolio

1.2 Sustainable Innovation

1.3 Regional Balance

**1.4 Team Excellence**

# We are “Team Excellence”

Derived from our core values – deeply rooted within Evonik

---



## Excellence

- We strive for excellence in everything we do – across businesses and functions
- We set ourselves ambitious targets
- We hold ourselves accountable to reach these targets (e.g. in compensation)

## Team

- We value all employees
- We foster collaboration and employee involvement through innovative approaches such as our “Open source change” program and an impactful feedback landscape

# Launched in 2023: Reorganization program Evonik Tailor Made

## Fostering a culture of employee empowerment and faster decision making

### Overarching idea of Evonik Tailor Made

**Business Lines  
as “nucleus” of Evonik**  
through shifting of responsibilities  
from corporate or division level

**Empowerment of individual employees  
and faster decision making**  
through reduction of hierarchy levels, increasing management  
span and cutting tasks without direct business relevance

**€400m**

Gross savings target  
until end of 2026

Personnel costs

**~80%**

Non-personnel costs

**~20%**

- Reduction of up to 2,000 employees by end of 2026
- Majority in administration & other support functions, remaining from business organizations
- Over-proportionally high number of management positions
- Max. 6 hierarchy levels below C-level (down from currently up to 10); management span<sup>1</sup> increasing from 1:4 to 1:7

e.g.:

- Agency & consulting costs
- Sport sponsoring

1. Number of employees per leadership position

**Click the table of contents to navigate chapters**

---

## **2 Segments**

### **2.1 Custom Solutions**

### **2.2 Advanced Technologies**

# Custom Solutions

Innovation-driven businesses with tailored and science-based solutions

FY 2025  
financials



Sales  
**€5.5 bn**



EBITDA  
**€909 m**



EBITDA Margin  
**17%**



ROCE  
**10%**

## Industrial Applications

### Additives



Sales:  
**€3.7 bn**

- Coating Additives
- Polyurethane Additives
- Lubricant Additives
- Other Industrial Additives
- Catalysts

### Care



Sales:  
**€1.8 bn**

- Home, Lifestyle, Personal Care
- Health Care

## Life Science Applications


### Common main characteristics across the whole segment



**Diverse and  
attractive markets**




**Product- and solution-  
driven innovation**



**Customer-centric  
business models**

# Leading in attractive markets

## Basis for resilient EBITDA growth in the coming years

End market split (in % of sales)	Sub-Segment	Selected relevant markets for Evonik	Market growth
	<b>Additives</b>	Additives for CASE <sup>2</sup> ..... ~4% Additives for agricultural industry ..... ~6% PU foams for next generation insulation materials in construction ..... ~5% <ul style="list-style-type: none"> <li>▪ #1 in Lubricant Additives</li> <li>▪ #1 in Polyurethane Additives</li> <li>▪ #2 in Coating Additives</li> </ul>	
	<b>Care</b>	Active ingredients for the cosmetics industry ..... ~5% Advanced delivery systems for the pharmaceutical industry ..... ~6% <ul style="list-style-type: none"> <li>▪ #2 in Active Ingredients</li> <li>▪ #2 in Oral Drug Delivery Systems</li> </ul>	

1. Pulp Paper & Packaging | 2. Coatings, Adhesives, Sealants, Elastomers (CASE)

# Topline growth enabled by recent investments in attractive areas

## Biosurfactants

### First world-scale plant for Rhamnolipids (biosurfactants)

Slovenská Ľupča, Slovakia



- Serving increasing demand of FMCG companies for renewable surfactants at superior performance
- Exploring further applications, e.g. industrial cleaning solutions and Coating Additives

## Polybutadienes

### New plant in Asia & expansion in Germany for HT Polybutadienes

Germany & China



- Reinforcing growth strategy by further strengthening the global production infrastructure
- POLYVEST® HT to serve increasing demand e.g. as high-quality binder for PU sealants

## Alkoxides

### New plant for Catalyst platform

Singapore



- Capacity expansion to supply growing demand for alkoxides used for e.g. biodiesel production and synthesis for pharmaceutical industry
- Future-ready: Alkoxides are needed for chemical recycling of plastics

# The Custom Solutions Segment – A strong growth driver for Evonik



# Click the table of contents to navigate chapters

---



## 2 Segments

### 2.1 Custom Solutions

### 2.2 **Advanced Technologies**

# Advanced Technologies


Leveraging technology- & asset-based competencies



*Common main characteristics across the whole segment*



# Strong position in wide range of attractive & growing markets

End market split	Sub-Segment	Leading Positions	Market growth
<p>in % of sales</p> 	<p><b>Organics</b></p>	<p>#1 Isophorone chemistry ..... #2 Long-chain Polyamides</p>	<p>~3% ..... ~5%</p>
	<p><b>Inorganics</b></p>	<p>#1 Precipitated and Fumed Silica ..... #2 Hydrogen Peroxide</p>	<p>~3% ..... ~6%</p>
	<p><b>Animal Nutrition</b></p>	<p>#1 Methionine</p>	<p>~3-4%</p>

1. e.g. Membranes

# Strong technology platforms as foundation

## Attractive growth opportunities in fast-growing niche markets

### Expansion Precipitated Silica (Silica)



**Charleston,  
US**

Planned start-up: Q2 2026

- Expansion of existing capacities for precipitated Silica
- Support growth of key tire OEMs in local value chain
- Providing circular silica to meet increasing sustainability needs

### Gas Separation Membranes (High Performance Polymers)




**Schörfling/  
Lenzing,  
Austria**

Planned start-up: End of 2026

- Capacity expansion for hollow fiber spinning plants in Schörfling, AT
- Addressing strong demand trajectory for sustainable membranes driven by renewable energy

### High-purity Hydrogen Peroxide (Hydrogen Peroxide)



**Several  
projects in  
all major  
regions**

- Several investments in Europe, North America and Asia
- Addressing fast growing demand for (ultra) high purity hydrogen peroxide (e.g. semiconductor, solar cell)

# Advanced Technologies Segment – an attractive and essential part of Evonik

## Advanced Technologies



We leverage our **strong market positions** and production platforms



We use our special **technological competence** to make the difference



We implement **operational improvements** consistently



We are **committed to deliver on Evonik's targets**

# Click the table of contents to navigate chapters

---

## 3 Financials

### 3.1 Main KPI's

### 3.2 Financial Strategy

# FY 2025 results overview

Sales (in € m)

**14,069**

(FY 2024: 15,157)

Sales (yoy in %)

Volume

**-2%**

FX

**-2%**

Price

**-1%**

Other

**-2%**

Adj. EBITDA (in € m)

**1,874**

(FY 2024: 2,065)

Free Cash Flow (in € m) / CCR<sup>1</sup>

**695**

(FY 2024: 873)

**37%**

(FY 2024: 42%)

ROCE (in %)

**6.1**

(FY 2024: 7.1)

Adj. EPS (in €)

**1.36**


(FY 2024: 1.67)

1. Cash Conversion Rate = FCF / adj. EBITDA

# While the short-term trading environment remains tough, our strategic direction remains valid and we control our own destiny



# Capital allocation priorities remain unchanged – new dividend policy based on payout ratio



1. From FY 2026 (paid in 2027) onwards; €1 per share as transition for FY 2025 (paid in 2026)

# New dividend policy: Combining an attractive dividend with increased financial flexibility

## New dividend policy to be established in two steps

1

Dividend proposal  
for FY 2025  
(to be paid  
in 2026)

€1  
per share

- Rigid dividend of €1.17 not adequate in this tough market environment and for a company in transformation
- Transition year from the past's fixed dividend level to a payout ratio in the future
- €1 per share highly attractive dividend in these difficult times: ~7% yield<sup>1</sup>

- Dividend tied to financial performance enables
  - Long-term sustainability of dividend
  - More financial flexibility for Evonik to reach its strategic and financial targets
  - Participation of investors in future growth
- Range for payout ratio allows for dividend continuity and reliability in Euro terms (i.e. higher payout ratio in weaker financial years and vice versa)

2


From  
FY 2026  
onwards  
(to be paid  
from 2027)

40-60%  
payout ratio  
based on  
adj. net income

1. Based on share price level on February 4, 2026

# Spotlight on CAPEX: Guiding principles for a balanced approach

~€750 m per year



Capex categories


- Focused on attractive pockets of growth
- Next Generation Solutions with superior sustainability profile
- IRR > ROCE target (11%)



- Small-sized growth projects
- Highly ROCE-accretive, with fast payback <2 years



- Preserve technology leadership & leading market positions
- Next Generation Technologies (~€80 m p.a.) to improve energy-efficient processes
- Asset maintenance & legal requirements



1. 2030 target: >50% of total sales generated by Next Generation Solutions products | 2. 2030 target: 25% reduction of GHG gross emissions; reference year 2021, target year 2030, SBTi approved

# Spotlight on “immediate return” projects

**~10%**  
of total capex<sup>1</sup>

**>50%**  
IRR on average

**+1 pp**  
ROCE<sup>2</sup>

**<€2.5 m**  
capex per project

**~1-2 years**  
payback time

**Project types**

**Rationalization and small debottlenecking projects that increase yield or throughput**




## Typical examples

- Expansion of columns
- Replacement/expansion of heat pumps and exchangers
- Refurbishment of filling lines/storage container


1. % out of ~€750 m capex planned 2026-2027 | 2. Expected ROCE increase through implementation of immediate return projects until 2027

# Five-year financial review


## Sales (in € bn)




## Adj. EBITDA / Margin (in € m / in %)



## Free Cash Flow / Cash Conversion (in € m / in %)



## ROCE (in %)




# Management compensation

<p>Fixed salary ~1/3</p>	<p>To be paid in cash for each financial year</p>	
<p>Bonus ~1/3</p>	<p><b>KPIs aligned to mid-term strategic targets</b></p> <ol style="list-style-type: none"> <li>1. Progression towards EBITDA margin target</li> <li>2. EBITDA growth (yoy)</li> <li>3. Contribution to FCF target</li> </ol>	<p>... <b>and integrating Safety First mindset</b></p> <ol style="list-style-type: none"> <li>4. <b>Accident performance</b></li> </ol>
<p>Long-term incentive plan ~1/3</p>	<p><b>80%</b> share price</p> <ul style="list-style-type: none"> <li>▪ Granted LTI target amount calculated in virtual shares (4-year lock-up)</li> <li>▪ Absolute performance: Real price of the Evonik share</li> <li>▪ Relative performance against external index benchmark (MSCI Chemicals)</li> </ul>	<p><b>20%</b> ESG</p> <p>LTI based on strategic ESG KPI's, e.g.:</p> <ul style="list-style-type: none"> <li>▪ <b>40%: Sales share of "Next Generation Solutions"</b></li> <li>▪ <b>40%: CO<sub>2</sub> emission reduction</b></li> <li>▪ <b>20%: Social Index</b></li> </ul>

# Procurement volume split & breakdown of raw material spend

## Total procurement volume 2025



## Breakdown of raw material spend (examples)

### Bio


- Dextrose
- Fatty alcohols
- Fatty acids
- Tallow fatty acid

### Inorganics & others

- Sodium silicate
- Sodium hydroxide
- Silicon metal

### Fossil<sup>2</sup>

- Crack C4
- Propene
- Acetone
- Methanol
- Methyl methacrylate



### Custom Solutions

Methyl methacrylate  
Methanol  
Fatty acids

### Advanced Technologies

Propene  
Dextrose  
Sodium silicate

### Infrastructure & Others

Crack C4  
Methanol  
Hydrogen

1: Gross energy bill, not considering the selling to external parties | 2: Fossil raws from base petrochemicals and synthetic organic markets

# Click the table of contents to navigate chapters

---


## 3 Financials

### 3.1 Main KPI's

### 3.2 Financial Strategy


# Financing strategy: Conservative, forward-looking and sustainable

## Conservative Liquidity Profile



- **Ample liquidity sources**
- **Syndicated credit facility** (“5+1+1”) extended to **maximum maturity 2029**

## Well-balanced capital market maturity profile




- **Bonds** as main financing instrument, preference for **“green”**
  - Ø coupon of 2.11% p.a. on €1.75 bn senior bonds
  - Ø coupon of 3.51% p.a. on €0.67 bn hybrid bonds
- **Refinancing well ahead of time**

## Strong commitment to a solid investment grade rating

1. 2026: Formal lifetime 60 years with first redemption right for Evonik in 2026; 2031: formal lifetime 30 years with first redemption right for Evonik in 2031

# ESG integration

## Green bonds firmly established – supporting our sustainability strategy



### Use of proceeds

Aligned with ICMA Green Bond Principles


**Green Finance Framework** 2023

Eligibility categories and allocation share per category in % <sup>2</sup>	
1. <b>Eco-efficient products:</b> Capex and RD&I Opex for <b>Next Generation Solutions</b>	94
2. <b>Energy Efficiency:</b> Expenditure for ongoing development of production processes and infrastructure to reduce GHG emissions (e.g. <b>Next Generation Technologies</b> )	6
3. <b>Renewable Energy:</b> Expenditure related to sourcing of renewable energy	-

1. Allocation & Impact-Reporting planned from 2026; 2. Based on allocation of net proceeds from 2021 green hybrid bonds and 2022 green senior bond

# Evonik has a strong rating track record

## BBB+ stable by S&P and Baa2 positive by Moody's



**S&P** rating remains unchanged at **BBB+ stable** since 2012

**Moody's** rating at **Baa2** since 2021, **outlook raised to positive in May 2025**

Both rating agencies acknowledge

- a strong business profile of Evonik underpinned by significant size and leading global market positions
- greater-than-peer diversity in terms of end-markets and product range
- strong commitment to a solid investment grade rating

# Evonik Investor Relations Team

---



**Christoph Finke**  
Senior Vice President Investor Relations

+49 174 9931647  
christoph.finke@evonik.com



**Cédric Schupp**  
Director Investor Relations & ESG

+49 173 2552453  
cedric.schupp@evonik.com



**Katharina Gayk**  
Specialist Investor Relations

+49 174 9931669  
katharina.gayk@evonik.com



**Johanna Göbel**  
Senior Manager Investor Relations

+49 172 5268167  
johanna.goebel@evonik.com



**Janine Göttel**  
Specialist Investor Relations

+49 151 53831578  
janine.goettel@evonik.com



**Gevitha Selvakumar**  
Manager Investor Relations & ESG

+49 174 9080817  
gevitha.selvakumar@evonik.com



**EVONIK**

**Leading Beyond Chemistry**

## Disclaimer

In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.